Boston Partners acquired a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 69,083 shares of the company's stock, valued at approximately $915,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TAK. PDS Planning Inc lifted its stake in shares of Takeda Pharmaceutical by 50.9% in the fourth quarter. PDS Planning Inc now owns 15,759 shares of the company's stock worth $209,000 after acquiring an additional 5,316 shares in the last quarter. Signaturefd LLC raised its position in shares of Takeda Pharmaceutical by 43.7% in the 4th quarter. Signaturefd LLC now owns 65,097 shares of the company's stock valued at $862,000 after purchasing an additional 19,786 shares in the last quarter. Gold Investment Management Ltd. boosted its stake in shares of Takeda Pharmaceutical by 12.2% during the 4th quarter. Gold Investment Management Ltd. now owns 82,147 shares of the company's stock valued at $1,088,000 after buying an additional 8,943 shares during the last quarter. Corient Private Wealth LLC grew its position in shares of Takeda Pharmaceutical by 15.0% during the fourth quarter. Corient Private Wealth LLC now owns 124,908 shares of the company's stock worth $1,654,000 after buying an additional 16,311 shares in the last quarter. Finally, Natixis Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 4.7% in the fourth quarter. Natixis Advisors LLC now owns 478,579 shares of the company's stock worth $6,336,000 after buying an additional 21,539 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.
Takeda Pharmaceutical Stock Up 0.6 %
TAK traded up $0.09 during trading on Tuesday, hitting $15.10. The company had a trading volume of 221,578 shares, compared to its average volume of 1,758,321. The company has a market cap of $48.03 billion, a PE ratio of 37.74, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.31. The business has a 50-day moving average of $14.00 and a 200-day moving average of $13.91.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
